EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 234 filers reported holding EXELIXIS INC in Q4 2016. The put-call ratio across all filers is 0.89 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $1,549,314 | -44.1% | 68,889 | -41.0% | 0.00% | – |
Q1 2024 | $2,770,715 | +189.0% | 116,760 | +193.9% | 0.00% | – |
Q4 2023 | $958,589 | +18.8% | 39,726 | +9.0% | 0.00% | – |
Q3 2023 | $806,759 | -79.1% | 36,439 | -81.9% | 0.00% | -100.0% |
Q2 2023 | $3,858,844 | +23.8% | 201,401 | +25.7% | 0.00% | 0.0% |
Q1 2023 | $3,116,259 | +13.2% | 160,219 | -6.5% | 0.00% | 0.0% |
Q4 2022 | $2,753,198 | +74.9% | 171,432 | +72.6% | 0.00% | 0.0% |
Q3 2022 | $1,574,000 | +96.0% | 99,326 | +173.5% | 0.00% | – |
Q2 2022 | $803,000 | +3.7% | 36,315 | +5.3% | 0.00% | – |
Q1 2022 | $774,000 | -46.2% | 34,494 | -55.3% | 0.00% | -100.0% |
Q4 2021 | $1,438,000 | -96.8% | 77,156 | -96.5% | 0.00% | -95.2% |
Q3 2021 | $45,612,000 | +12.3% | 2,186,634 | -3.4% | 0.02% | +5.0% |
Q2 2021 | $40,626,000 | -0.7% | 2,263,311 | +29.2% | 0.02% | -25.9% |
Q1 2021 | $40,923,000 | +1.4% | 1,751,818 | +4.8% | 0.03% | 0.0% |
Q4 2020 | $40,358,000 | -5.6% | 1,671,146 | -8.1% | 0.03% | -25.0% |
Q3 2020 | $42,757,000 | -10.1% | 1,818,625 | -7.5% | 0.04% | -16.3% |
Q2 2020 | $47,561,000 | -24.2% | 1,966,905 | -47.8% | 0.04% | -40.3% |
Q1 2020 | $62,713,000 | -9.0% | 3,766,521 | -3.7% | 0.07% | +38.5% |
Q4 2019 | $68,894,000 | +657.4% | 3,909,944 | +660.1% | 0.05% | +550.0% |
Q3 2019 | $9,096,000 | -19.2% | 514,365 | -2.3% | 0.01% | -11.1% |
Q2 2019 | $11,253,000 | -12.2% | 526,558 | -2.2% | 0.01% | -18.2% |
Q1 2019 | $12,813,000 | +53.8% | 538,455 | +27.1% | 0.01% | +37.5% |
Q4 2018 | $8,331,000 | +15.5% | 423,569 | +4.0% | 0.01% | +33.3% |
Q3 2018 | $7,215,000 | -10.8% | 407,200 | +8.4% | 0.01% | -14.3% |
Q2 2018 | $8,085,000 | -58.0% | 375,734 | -56.8% | 0.01% | -58.8% |
Q1 2018 | $19,272,000 | -45.3% | 870,106 | -25.0% | 0.02% | -45.2% |
Q4 2017 | $35,263,000 | +64.8% | 1,159,964 | +31.4% | 0.03% | +55.0% |
Q3 2017 | $21,397,000 | +628.5% | 883,056 | +640.6% | 0.02% | +566.7% |
Q2 2017 | $2,937,000 | -23.6% | 119,243 | -32.8% | 0.00% | -25.0% |
Q1 2017 | $3,845,000 | -2.0% | 177,403 | -23.5% | 0.00% | 0.0% |
Q4 2016 | $3,922,000 | +164.5% | 231,765 | +99.8% | 0.00% | +100.0% |
Q3 2016 | $1,483,000 | +99.3% | 116,024 | +21.9% | 0.00% | +100.0% |
Q2 2016 | $744,000 | +95.8% | 95,200 | +0.2% | 0.00% | – |
Q1 2016 | $380,000 | -29.4% | 95,026 | -0.4% | 0.00% | -100.0% |
Q4 2015 | $538,000 | +8866.7% | 95,377 | +9196.0% | 0.00% | – |
Q3 2015 | $6,000 | +50.0% | 1,026 | 0.0% | 0.00% | – |
Q2 2015 | $4,000 | +33.3% | 1,026 | 0.0% | 0.00% | – |
Q1 2015 | $3,000 | +200.0% | 1,026 | 0.0% | 0.00% | – |
Q4 2014 | $1,000 | -94.1% | 1,026 | -79.1% | 0.00% | – |
Q2 2014 | $17,000 | -5.6% | 4,910 | +63.7% | 0.00% | – |
Q4 2013 | $18,000 | +5.9% | 3,000 | 0.0% | 0.00% | – |
Q3 2013 | $17,000 | +21.4% | 3,000 | 0.0% | 0.00% | – |
Q2 2013 | $14,000 | – | 3,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Meditor Group Ltd | 11,275,871 | $254,722,000 | 71.55% |
GREAT POINT PARTNERS LLC | 1,201,100 | $27,133,000 | 5.61% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 886,534 | $20,027,000 | 5.30% |
Sargent Investment Group, LLC | 498,350 | $11,258,000 | 2.96% |
CAPITAL MANAGEMENT CORP /VA | 311,660 | $7,040,000 | 1.57% |
EULAV Asset Management | 2,460,000 | $55,571,000 | 1.49% |
CM Management, LLC | 80,000 | $1,807,000 | 1.34% |
Integral Health Asset Management, LLC | 200,000 | $4,518,000 | 1.29% |
FARALLON CAPITAL MANAGEMENT LLC | 10,750,000 | $242,843,000 | 1.21% |
Sofinnova Investments, Inc. | 839,181 | $18,957,000 | 1.14% |